Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule
- 27 December 2010
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (2) , 739-744
- https://doi.org/10.1073/pnas.1017677108
Abstract
One of the two essential virulence factors of Bacillus anthracis is the poly-γ-D-glutamic acid (γDPGA) capsule. Five γDPGA-specific antibody antigen-binding fragments (Fabs) were generated from immunized chimpanzees. The two selected for further study, Fabs 11D and 4C, were both converted into full-length IgG1 and IgG3 mAbs having human IgG1 or IgG3 constant regions. These two mAbs had similar binding affinities, in vitro opsonophagocytic activities, and in vivo efficacies, with the IgG1 and IgG3 subclasses reacting similarly. The mAbs bound to γDPGA specifically with estimated binding affinities (K(d)) of 35-70 nM and effective affinities (effective K(d)) of 0.1-0.3 nM. The LD(50) in an opsonophagocytic bactericidal assay was ≈10 ng/mL of 11D or 4C. A single 30-μg dose of either mAb given to BALB/c mice 18 h before challenge conferred about 50% protection against a lethal intratracheal spore challenge by the virulent B. anthracis Ames strain. More importantly, either mAb given 8 h or 20 h after challenge provided significant protection against lethal infection. Thus, these anti-γDPGA mAbs should be useful, alone or in combination with antitoxin mAbs, for achieving a safe and efficacious postexposure therapy for anthrax.Keywords
This publication has 34 references indexed in Scilit:
- Novel Chimpanzee/Human Monoclonal Antibodies That Neutralize Anthrax Lethal Factor, and Evidence for Possible Synergy with Anti-Protective Antigen AntibodyInfection and Immunity, 2009
- Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor bindingProceedings of the National Academy of Sciences, 2009
- Association of Bacillus anthracis Capsule with Lethal Toxin during Experimental InfectionInfection and Immunity, 2009
- Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection ModelJournal of Virology, 2007
- Protective and Immunochemical Activities of Monoclonal Antibodies Reactive with theBacillus anthracisPolypeptide CapsuleInfection and Immunity, 2007
- Poly-γ-Glutamate Capsule-Degrading Enzyme Treatment Enhances Phagocytosis and Killing of EncapsulatedBacillus anthracisAntimicrobial Agents and Chemotherapy, 2007
- Toxin-Deficient Mutants of Bacillus anthracis Are Lethal in a Murine Model for Pulmonary AnthraxInfection and Immunity, 2006
- Efficient Neutralization of Anthrax Toxin by Chimpanzee Monoclonal Antibodies against Protective AntigenThe Journal of Infectious Diseases, 2006
- Immunogenicity and Protective Efficacy of Bacillus anthracis Poly-γ-d-glutamic Acid Capsule Covalently Coupled to a Protein Carrier Using a Novel Triazine-based Conjugation StrategyJournal of Biological Chemistry, 2006
- The Capsule of Bacillus anthracis Behaves as a Thymus-Independent Type 2 AntigenInfection and Immunity, 2004